Precision Steps: Can Loxo Drug Help Broaden Use of Cancer DNA Tests?
Xconomy
JUNE 3, 2017
When the FDA last week approved Merck’s cancer drug pembrolizuamb (Keytruda) for tumors with a specific genetic signature , regardless of what body part they originated in, it was a watershed moment for oncology and a victory for the concept of precision medicine. But Merck isn’t alone; others are following suit with similar plans, and their progress is worth watching.
79 
Let's personalize your content